Is p38 MAPK a Dark Force in Right Ventricular Hypertrophy and Failure in Pulmonary Arterial Hypertension?

about

Is p38 MAPK a Dark Force in Right Ventricular Hypertrophy and Failure in Pulmonary Arterial Hypertension?

Item

http://www.wikidata.org/entity/Q47667173

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Is p38 MAPK a Dark Force in Ri ...... lmonary Arterial Hypertension?

@en

Is p38 MAPK a Dark Force in Ri ...... lmonary Arterial Hypertension?

@nl

type

Item

label

Is p38 MAPK a Dark Force in Ri ...... lmonary Arterial Hypertension?

@en

Is p38 MAPK a Dark Force in Ri ...... lmonary Arterial Hypertension?

@nl

prefLabel

Is p38 MAPK a Dark Force in Ri ...... lmonary Arterial Hypertension?

@en

Is p38 MAPK a Dark Force in Ri ...... lmonary Arterial Hypertension?

@nl

P1476

Is p38 MAPK a Dark Force in Ri ...... lmonary Arterial Hypertension?

@en

P2093

Franz Rischard

http://www.w3.org/2001/XMLSchema#string

Haiyang Tang

http://www.w3.org/2001/XMLSchema#string

Jason X-J Yuan

http://www.w3.org/2001/XMLSchema#string

Rebecca R Vanderpool

http://www.w3.org/2001/XMLSchema#string

P2860

Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt.

Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype.

The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension.

A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo.

Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction

Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology.

p38 MAPK Inhibition Improves Heart Function in Pressure Loaded Right Ventricular Hypertrophy.

Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload.

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

P304

506-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1165/RCMB.2017-0197ED

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29090954

http://www.w3.org/2001/XMLSchema#string

P932

5705908

http://www.w3.org/2001/XMLSchema#string